News Sentiment

ELTX sentiment intelligence

Elicio Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.48 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+8.1% over one week, -76.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Enterprise value to revenue forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction 8.1% Price confirming higher
Trend fit Trend inactive -76.6% over four weeks
Fair value -53.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 28
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
Stock Titan 7
TradingView 6
GlobeNewswire 4
Investing.com 4
simplywall.st 4
The National Law Review 3
ACCESS Newswire 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 11
Regulatory and legal 5
Balance sheet 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
TradingView Direct company coverage

Enterprise value to revenue forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX

The article presents the enterprise value to revenue forward for Elicio Therapeutics, Inc. (NASDAQ: ELTX) on TradingView. It appears to be a financial data snippet or a specific metric displayed on the platform for the biotechnology company. The content primarily focuses on prese

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 17:39
Source
TradingView
PR Newswire Direct company coverage

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX

Pomerantz LLP has launched an investigation into Elicio Therapeutics, Inc. (NASDAQ: ELTX) following a significant drop in its stock price. The investigation concerns potential securities fraud or unlawful business practices after Elicio reported that its Phase 2 AMPLIFY-7P Study

Tone
Negative 14/100
Event
Regulatory and legal
Published
09 Jul 2026 17:11
Source
PR Newswire
Stock Titan Direct company coverage

[SCHEDULE 13G/A] Elicio Therapeutics, Inc. Amended Passive Investment Disclosure

Knoll Capital Management, Fred Knoll, and Gakasa Holdings have filed an amended Schedule 13G/A for Elicio Therapeutics, Inc. (ELTX), reporting beneficial ownership of 1,211,957 shares, which represents 5.3% of the common stock. This filing indicates shared voting and shared dispo

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 18:39
Source
Stock Titan
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elicio Therapeutics, Inc. (ELTX) after the company announced its Phase 2 AMPLIFY-7P study failed to meet its primary endpoint, leading to a nearly 71% drop in its share price. The firm is encouraging shareholde

Tone
Negative 19/100
Event
Regulatory and legal
Published
08 Jul 2026 16:39
Source
ACCESS Newswire
GlobeNewswire Direct company coverage

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

Elicio Therapeutics announced the closing of a $15 million registered direct offering. The funds, raised from new and existing institutional investors, will primarily support the planned Phase 1 clinical development of ELI-002 7P for metastatic pancreatic ductal adenocarcinoma (P

Tone
Positive 66/100
Event
Market update
Published
07 Jul 2026 14:11
Source
GlobeNewswire
Investing.com Direct company coverage

Elicio Therapeutics closes $15 million stock offering

Elicio Therapeutics has successfully closed a $15 million direct stock offering, selling 4,380,313 shares to new institutional investors and existing shareholders. The biotechnology company plans to use the proceeds, along with existing funds, for the Phase 1 clinical development

Tone
Positive 66/100
Event
Market update
Published
06 Jul 2026 21:40
Source
Investing.com
Stock Titan Direct company coverage

Elicio closes $15M stock sale to fund KRAS cancer trial work

Elicio Therapeutics (Nasdaq: ELTX) has successfully closed a registered direct offering, raising approximately $15 million in gross proceeds through the sale of 4,380,313 shares of common stock. These funds, secured from institutional investors and an existing shareholder, will p

Tone
Positive 64/100
Event
Market update
Published
06 Jul 2026 19:40
Source
Stock Titan
The National Law Review Direct company coverage

Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Elicio Therapeutics, Inc. (ELTX) investors. The investigation follows a significant drop in Elicio's share price after the company announced its Phase 2 AMPLIFY-7P study did not meet its primary end

Tone
Negative 29/100
Event
Regulatory and legal
Published
05 Jul 2026 16:12
Source
The National Law Review
TradingView Direct company coverage

Enterprise value to EBIT forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX

This page provides financial information for Elicio Therapeutics, Inc. (NASDAQ: ELTX), specifically focusing on its enterprise value to EBIT forward ratio. The content appears to be a financial data page from TradingView, offering an overview of the company's financial metrics. H

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 13:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX

This page displays the "Price to sales forward" metric for Elicio Therapeutics, Inc. (NASDAQ: ELTX) on TradingView. It indicates that the market was closed with no trades at the time of viewing. The content provides navigational elements and company information related to Trading

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 04:39
Source
TradingView
Investing.com South Africa Direct company coverage

Elicio Therapeutics stock tumbles on $15M offering By Investing.com

Elicio Therapeutics Inc. (NASDAQ:ELTX) shares dropped 32.5% after announcing a $15 million registered direct offering. The funding, led by new institutional investors and an existing shareholder, will support the Phase 1 clinical development of ELI-002 7P for metastatic pancreati

Tone
Negative 30/100
Event
Market update
Published
02 Jul 2026 15:09
Source
Investing.com South Africa
Moomoo Direct company coverage

Elicio Therapeutics Intends to Use Net Proceeds From Offering to Fund Clinical Development >ELTX

Elicio Therapeutics plans to utilize the net proceeds from a public offering of common stock, pre-funded warrants, and common warrants to further fund the clinical development of its pipeline. A significant portion of these funds will be allocated towards advancing ELI-002, the c

Tone
Positive 60/100
Event
Market update
Published
02 Jul 2026 13:10
Source
Moomoo
Stock Titan Direct company coverage

Elicio Therapeutics (ELTX) raises ~$15.0M via 4.38M-share placement

Elicio Therapeutics (ELTX) has raised approximately $15.0 million through a registered offering of 4.38 million shares at $3.43 per share. The net proceeds of $13.6 million will primarily fund a planned Phase 1 study for ELI-002 7P in metastatic pancreatic cancer, advance its pip

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 12:39
Source
Stock Titan
StreetInsider Direct company coverage

Form 424B5 Elicio Therapeutics,

Elicio Therapeutics has filed a Form 424B5 prospectus supplement for the offering of 4,380,313 shares of common stock, aiming to raise approximately $13.6 million in net proceeds. The company, a clinical-stage biotechnology firm, plans to use these proceeds to fund the Phase 1 cl

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 12:09
Source
StreetInsider
Stock Titan Direct company coverage

Elicio Therapeutics (ELTX) prices $15M registered direct equity offering

Elicio Therapeutics (ELTX) has announced the pricing of a $15 million registered direct offering of 4,380,313 shares of common stock at $3.43 per share. The biotech company plans to use the net proceeds, along with its existing cash, primarily to fund the planned Phase 1 clinical

Tone
Neutral 50/100
Event
Balance sheet
Published
02 Jul 2026 10:40
Source
Stock Titan
TradingView Direct company coverage

Elicio Therapeutics Prices $15 Million Registered Direct Offering at $3.43; Signs Purchase, Placement Pacts

Elicio Therapeutics has announced a $15 million registered direct offering of 4,380,313 common shares priced at $3.43 each, expected to close on July 6, 2026. The company has entered into a Securities Purchase Agreement with institutional investors and a separate Placement Agency

Tone
Negative 38/100
Event
Market update
Published
02 Jul 2026 10:40
Source
TradingView
marketscreener.com Direct company coverage

Elicio Therapeutics Prices $15 Million Direct Offering

Elicio Therapeutics has priced a $15 million direct offering. The company is a clinical-stage biotechnology firm developing immunotherapies for cancer, including vaccines targeting mutated KRAS, BRAF, and TP53. Recent news includes mixed results from their ELI-002 Phase 2 study f

Tone
Negative 33/100
Event
Earnings
Published
02 Jul 2026 07:40
Source
marketscreener.com
Stock Titan Direct company coverage

Elicio locks in $15M to fund Phase 1 KRAS cancer trial

Elicio Therapeutics (Nasdaq: ELTX) announced a registered direct offering to raise approximately $15 million. The funding, led by new institutional investors and a large existing shareholder, will primarily support the planned Phase 1 development of ELI-002 7P for metastatic PDAC

Tone
Negative 31/100
Event
Market update
Published
02 Jul 2026 06:40
Source
Stock Titan
Investing.com Direct company coverage

Elicio Therapeutics raises $15M in registered direct offering

Elicio Therapeutics (NASDAQ:ELTX) has announced a registered direct offering to raise approximately $15 million from two new institutional investors and an existing shareholder. The funds will be used to advance the Phase 1 clinical development of ELI-002 7P for metastatic pancre

Tone
Positive 70/100
Event
Market update
Published
02 Jul 2026 04:40
Source
Investing.com
GlobeNewswire Direct company coverage

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

Elicio Therapeutics has announced the pricing of a registered direct offering totaling $15 million, led by new institutional investors and an existing shareholder. The proceeds will primarily fund the Phase 1 clinical development of ELI-002 7P for metastatic PDAC, expand Elicio’s

Tone
Positive 60/100
Event
Market update
Published
02 Jul 2026 04:40
Source
GlobeNewswire
Quiver Quantitative Direct company coverage

Elicio Therapeutics Announces $15 Million Registered Direct Offering to Fund ELI-002 7P Clinical Development

Elicio Therapeutics has announced a $15 million registered direct offering to fund the Phase 1 clinical development of ELI-002 7P for metastatic pancreatic cancer, with new institutional investors and an existing shareholder participating. The net proceeds, along with existing ca

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 04:30
Source
Quiver Quantitative
TradingView Direct company coverage

Price to book forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX

This page from TradingView provides financial information for Elicio Therapeutics, Inc. (NASDAQ: ELTX), specifically focusing on its forward price-to-book ratio. The content appears to be a financial data page rather than a detailed news article, offering an overview of the compa

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:40
Source
TradingView
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elicio Therapeutics, Inc. (ELTX) following a significant drop in its share price. This investigation comes after Elicio announced that its Phase 2 AMPLIFY-7P study failed to meet its primary endpoint of disease

Tone
Negative 30/100
Event
Regulatory and legal
Published
01 Jul 2026 16:39
Source
ACCESS Newswire
The National Law Review Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therap

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elicio Therapeutics, Inc. (NASDAQ:ELTX) after the company announced its Phase 2 AMPLIFY-7P study did not meet its primary endpoint of disease-free survival, causing shares to fall by a

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 15:09
Source
The National Law Review
www.marketscreener.com Direct company coverage

Elicio Therapeutics, Inc.(NasdaqCM: ELTX) added to Russell 2500 Growth Benchmark

Elicio Therapeutics, Inc. (ELTX) has been added to the Russell 2500 Growth Benchmark. The clinical-stage biotechnology company focuses on developing immunotherapies for cancer, utilizing its amphiphile (AMP) platform to deliver immunotherapeutics directly to lymph nodes. The comp

Tone
Positive 65/100
Event
Market update
Published
29 Jun 2026 19:40
Source
www.marketscreener.com
The National Law Review Direct company coverage

Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elicio Therapeutics, Inc. (ELTX) following a significant 71% drop in its share price. This decline occurred after the company announced that its Phase 2 AMPLIFY-7P study did not meet its primary endpoint of dis

Tone
Negative 18/100
Event
Regulatory and legal
Published
29 Jun 2026 15:40
Source
The National Law Review